Hpcort 6 Tablet contains Deflazacort 6 mg, a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory, allergic, and autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematosus, asthma, and certain dermatologic disorders. Deflazacort exerts its therapeutic effects by modulating the immune response and inhibiting the release of inflammatory mediators, thereby reducing tissue inflammation and immune system activity. The drug is also utilized in the treatment of certain muscular dystrophies to improve muscle strength and function. Hpcort 6 should be administered under medical supervision, with dosage tailored according to the severity of the condition and patient response. It is essential to monitor patients for potential adverse effects, including but not limited to hyperglycemia, hypertension, osteoporosis, and increased susceptibility to infections. Abrupt discontinuation should be avoided to prevent adrenal insufficiency; gradual tapering is recommended when discontinuing therapy. Caution is advised in patients with pre-existing conditions such as diabetes, hypertension, or peptic ulcers. Hpcort 6 Tablet is contraindicated in systemic fungal infections and hypersensitivity to Deflazacort or its components. Proper patient education regarding adherence and monitoring is crucial to optimize therapeutic outcomes while minimizing risks.